{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:43:59Z","timestamp":1773409439002,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,12,20]],"date-time":"2013-12-20T00:00:00Z","timestamp":1387497600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s10147-013-0651-5","type":"journal-article","created":{"date-parts":[[2013,12,20]],"date-time":"2013-12-20T18:22:30Z","timestamp":1387563750000},"page":"10-15","source":"Crossref","is-referenced-by-count":9,"title":["Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome"],"prefix":"10.1007","volume":"19","author":[{"given":"Takayuki","family":"Ishikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,12,20]]},"reference":[{"key":"651_CR1","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1056\/NEJMra0902908","volume":"361","author":"A Tefferi","year":"2009","unstructured":"Tefferi A, Vardiman JW (2009) Myelodysplastic syndromes. N Engl J Med 361:1872\u20131885","journal-title":"N Engl J Med"},{"key":"651_CR2","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J et al (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:2454\u20132465","journal-title":"Blood"},{"key":"651_CR3","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1053\/j.seminoncol.2011.04.012","volume":"38","author":"S Parmar","year":"2011","unstructured":"Parmar S, de Lima M, Deeg HJ et al (2011) Hematopoietic stem cell transplantation for myelodysplastic syndrome: a review. Semin Oncol 38:693\u2013704","journal-title":"Semin Oncol"},{"key":"651_CR4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.7326\/0003-4819-85-2-237","volume":"85","author":"DD Hoff Von","year":"1976","unstructured":"Von Hoff DD, Slavik M, Muggia FM (1976) 5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia. Ann Intern Med 85:237\u2013245","journal-title":"Ann Intern Med"},{"key":"651_CR5","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0163-7258(85)90052-X","volume":"30","author":"RL Momparler","year":"1985","unstructured":"Momparler RL, Rivard GE, Gyger M (1985) Clinical trial on 5-aza-2\u2032-deoxycytidine in patients with acute leukemia. Pharmacol Ther 30:277\u2013286","journal-title":"Pharmacol Ther"},{"key":"651_CR6","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/267364a0","volume":"267","author":"PG Constantinides","year":"1977","unstructured":"Constantinides PG, Jones PA, Gevers W (1977) Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment. Nature 267:364\u2013366","journal-title":"Nature"},{"key":"651_CR7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0092-8674(81)90248-8","volume":"25","author":"SJ Compere","year":"1981","unstructured":"Compere SJ, Palmiter RD (1981) DNA methylation controls the inducibility of the mouse metallothionein-I gene lymphoid cells. Cell 25:233\u2013240","journal-title":"Cell"},{"key":"651_CR8","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/blood.V64.4.922.922","volume":"64","author":"A Pinto","year":"1984","unstructured":"Pinto A, Attadia V, Fusco A et al (1984) 5-Aza-2\u2032-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 64:922\u2013929","journal-title":"Blood"},{"issue":"Suppl 1","key":"651_CR9","first-page":"21","volume":"7","author":"LR Silverman","year":"1993","unstructured":"Silverman LR, Holland JF, Weinberg RS et al (1993) Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 7(Suppl 1):21\u201329","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"651_CR10","first-page":"30","volume":"7","author":"V Zagonel","year":"1993","unstructured":"Zagonel V, Lo Re G, Marotta G et al (1993) 5-Aza-2\u2032-deoxycytidine (decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia 7(Suppl 1):30\u201335","journal-title":"Leukemia"},{"key":"651_CR11","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","volume":"20","author":"LR Silverman","year":"2002","unstructured":"Silverman LR, Demakos EP, Peterson BL et al (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20:2429\u20132440","journal-title":"J Clin Oncol"},{"key":"651_CR12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223\u2013232","journal-title":"Lancet Oncol"},{"key":"651_CR13","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2010.08082.x","volume":"149","author":"P Fenaux","year":"2010","unstructured":"Fenaux P, Gattermann N, Seymour JF et al (2010) Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol 149:244\u2013249","journal-title":"Br J Haematol"},{"key":"651_CR14","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.critrevonc.2010.04.005","volume":"76","author":"JF Seymour","year":"2010","unstructured":"Seymour JF, Fenaux P, Silverman LR et al (2010) Effects of azacitidine compared with conventional care regimens in elderly (\u226575\u00a0years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 76:218\u2013227","journal-title":"Crit Rev Oncol Hematol"},{"key":"651_CR15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1365-2141.2001.02933.x","volume":"114","author":"M Lubbert","year":"2001","unstructured":"Lubbert M, Wijermans P, Kunzmann R et al (2001) Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2\u2032-deoxycytidine. Br J Haematol 114:349\u2013357","journal-title":"Br J Haematol"},{"key":"651_CR16","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","volume":"106","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Issa JP, Rosenfeld CS et al (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106:1794\u20131803","journal-title":"Cancer"},{"key":"651_CR17","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","volume":"29","author":"M Lubbert","year":"2011","unstructured":"Lubbert M, Suciu S, Baila L et al (2011) Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 29:1987\u20131996","journal-title":"J Clin Oncol"},{"key":"651_CR18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/cncr.22376","volume":"109","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, O\u2019Brien S, Shan J et al (2007) Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 109:265\u2013273","journal-title":"Cancer"},{"key":"651_CR19","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1111\/j.1349-7006.2011.01993.x","volume":"102","author":"T Uchida","year":"2011","unstructured":"Uchida T, Ogawa Y, Kobayashi Y et al (2011) Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes. Cancer Sci 102:1680\u20131686","journal-title":"Cancer Sci"},{"key":"651_CR20","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2008.17.1058","volume":"27","author":"RM Lyons","year":"2009","unstructured":"Lyons RM, Cosgriff TM, Modi SS et al (2009) Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 27:1850\u20131856","journal-title":"J Clin Oncol"},{"key":"651_CR21","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/cncr.24894","volume":"116","author":"P Musto","year":"2010","unstructured":"Musto P, Maurillo L, Spagnoli A et al (2010) Azacitidine for the treatment of lower risk myelodysplastic syndromes: a retrospective study of 74 patients enrolled in an Italian named patient program. Cancer 116:1485\u20131494","journal-title":"Cancer"},{"key":"651_CR22","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1158\/1078-0432.CCR-12-3540","volume":"19","author":"C Fili","year":"2013","unstructured":"Fili C, Malagola M, Follo MY et al (2013) Prospective phase II study on 5-days azacitidine for treatment of symptomatic and\/or erythropoietin unresponsive patients with low\/INT-1-risk myelodysplastic syndromes. Clin Cancer Res 19:3297\u20133308","journal-title":"Clin Cancer Res"},{"key":"651_CR23","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/blood-2010-06-289280","volume":"117","author":"R Itzykson","year":"2011","unstructured":"Itzykson R, Thepot S, Quesnel B et al (2011) Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 117:403\u2013411","journal-title":"Blood"},{"key":"651_CR24","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","volume":"29","author":"T Prebet","year":"2011","unstructured":"Prebet T, Gore SD, Esterni B et al (2011) Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 29:3322\u20133327","journal-title":"J Clin Oncol"},{"key":"651_CR25","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.leukres.2004.11.022","volume":"29","author":"H Yang","year":"2005","unstructured":"Yang H, Hoshino K, Sanchez-Gonzalez B et al (2005) Antileukemia activity of the combination of 5-aza-2\u2032-deoxycytidine with valproic acid. Leuk Res 29:739\u2013748","journal-title":"Leuk Res"},{"key":"651_CR26","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2007-06-098061","volume":"111","author":"G Garcia-Manero","year":"2008","unstructured":"Garcia-Manero G, Yang H, Bueso-Ramos C et al (2008) Phase 1 study of the histone deacetylase inhibitor vorinostat [suberoylanilide hydroxamic acid (SAHA)] in patients with advanced leukemias and myelodysplastic syndromes. Blood 111:1060\u20131066","journal-title":"Blood"},{"key":"651_CR27","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1182\/blood-2006-03-009142","volume":"108","author":"G Garcia-Manero","year":"2006","unstructured":"Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B et al (2006) Phase 1\/2 study of the combination of 5-aza-2\u2032-deoxycytidine with valproic acid in patients with leukemia. Blood 108:3271\u20133279","journal-title":"Blood"},{"key":"651_CR28","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/leu.2013.26","volume":"27","author":"U Platzbecker","year":"2013","unstructured":"Platzbecker U, Braulke F, Kundgen A et al (2013) Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study. Leukemia 27:1403\u20131407","journal-title":"Leukemia"},{"key":"651_CR29","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1200\/JCO.2009.26.0745","volume":"28","author":"MA Sekeres","year":"2010","unstructured":"Sekeres MA, List AF, Cuthbertson D et al (2010) Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol 28:2253\u20132258","journal-title":"J Clin Oncol"},{"key":"651_CR30","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1182\/blood-2012-06-434639","volume":"120","author":"MA Sekeres","year":"2012","unstructured":"Sekeres MA, Tiu RV, Komrokji R et al (2012) Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood 120:4945\u20134951","journal-title":"Blood"},{"key":"651_CR31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.blre.2013.07.003","volume":"27","author":"AM Zeidan","year":"2013","unstructured":"Zeidan AM, Linhares Y, Gore SD (2013) Current therapy of myelodysplastic syndromes. Blood Rev 27:243\u2013259","journal-title":"Blood Rev"},{"key":"651_CR32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3109\/10428190903318329","volume":"51","author":"G Borthakur","year":"2010","unstructured":"Borthakur G, Huang X, Kantarjian H et al (2010) Report of a phase 1\/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma 51:73\u201378","journal-title":"Leuk Lymphoma"},{"key":"651_CR33","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3109\/10428194.2010.551570","volume":"52","author":"UD Bayraktar","year":"2011","unstructured":"Bayraktar UD, Domingo GC, Schmit J et al (2011) Azacitidine combined with gemtuzumab ozogamicin in patients with relapsed\/refractory acute myeloid leukemia. Leuk Lymphoma 52:913\u2013915","journal-title":"Leuk Lymphoma"},{"key":"651_CR34","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood-2010-03-274753","volume":"116","author":"HM Kantarjian","year":"2010","unstructured":"Kantarjian HM, Giles FJ, Greenberg PL et al (2010) Phase II study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 116:3163\u20133170","journal-title":"Blood"},{"key":"651_CR35","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3109\/10428194.2012.713477","volume":"54","author":"PL Greenberg","year":"2013","unstructured":"Greenberg PL, Garcia-Manero G, Moore M et al (2013) A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. Leuk Lymphoma 54:321\u2013328","journal-title":"Leuk Lymphoma"},{"key":"651_CR36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.bbmt.2004.10.001","volume":"11","author":"BL Scott","year":"2005","unstructured":"Scott BL, Storer B, Loken MR et al (2005) Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 11:65\u201373","journal-title":"Biol Blood Marrow Transplant"},{"key":"651_CR37","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/sj.leu.2403640","volume":"19","author":"K Nakai","year":"2005","unstructured":"Nakai K, Kanda Y, Fukuhara S et al (2005) Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia 19:396\u2013401","journal-title":"Leukemia"},{"key":"651_CR38","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1200\/JCO.2012.44.3499","volume":"30","author":"G Damaj","year":"2012","unstructured":"Damaj G, Duhamel A, Robin M et al (2012) Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. J Clin Oncol 30:4533\u20134540","journal-title":"J Clin Oncol"},{"key":"651_CR39","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.bbmt.2012.01.009","volume":"18","author":"AT Gerds","year":"2012","unstructured":"Gerds AT, Gooley TA, Estey EH et al (2012) Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant 18:1211\u20131218","journal-title":"Biol Blood Marrow Transplant"},{"key":"651_CR40","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1002\/cncr.25500","volume":"116","author":"M Lima de","year":"2010","unstructured":"de Lima M, Giralt S, Thall PF et al (2010) Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 116:5420\u20135431","journal-title":"Cancer"},{"key":"651_CR41","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/leu.2013.7","volume":"27","author":"T Schroeder","year":"2013","unstructured":"Schroeder T, Czibere A, Platzbecker U et al (2013) Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia 27:1229\u20131235","journal-title":"Leukemia"},{"key":"651_CR42","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/leu.2013.173","volume":"27","author":"EH Estey","year":"2013","unstructured":"Estey EH (2013) Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Leukemia 27:1803\u20131812","journal-title":"Leukemia"},{"key":"651_CR43","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s12185-012-1182-y","volume":"96","author":"S Ogawa","year":"2012","unstructured":"Ogawa S (2012) Splicing factor mutations in myelodysplasia. Int J Hematol 96:438\u2013442","journal-title":"Int J Hematol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-013-0651-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-013-0651-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-013-0651-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T18:07:23Z","timestamp":1597255643000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-013-0651-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,20]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["651"],"URL":"https:\/\/doi.org\/10.1007\/s10147-013-0651-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,20]]}}}